New Lungs for Lung Cancer—Perils and Promises | ClinicLens
Despite the recent advances in systemic therapy, survival for patients with metastatic non–small cell lung cancer (NSCLC) without actionable genomic alterations in the tumor is limited. A small subset of patients with NSCLC have lung-only metastatic disease and often die of progr
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.